NRI PULSE STAFF REPORT
Jersey City, NJ, May 5, 2026: In what is being described as the largest overseas acquisition ever by an Indian pharmaceutical company, Sun Pharmaceutical Industries has agreed to acquire U.S.-based Organon & Co. in a deal valued at approximately $11.75 billion to $12 billion, a move analysts say could propel the Indian drugmaker into the top tier of global pharmaceutical companies.
The acquisition marks a major milestone for billionaire founder Dilip Shanghvi and signals a broader shift in how Indian pharmaceutical firms are positioning themselves globally — moving beyond low-cost generic drugs toward specialty medicines, women’s health, and branded therapies.
According to Reuters and multiple financial publications, the all-cash deal would nearly double Sun Pharma’s annual revenue base to roughly $12 billion and significantly expand its international footprint across specialty pharmaceuticals and women’s healthcare.
Organon, headquartered in New Jersey, was spun off from Merck & Co. in 2021 and focuses on women’s health, fertility treatments, biosimilars, and established branded medicines. Its portfolio includes products such as Nexplanon, a contraceptive implant, and fertility drugs including Follistim.
Industry analysts say the acquisition gives Sun Pharma access to operations in approximately 140 countries and strengthens its presence in key international markets such as China and Brazil.
The deal is also being viewed as Sun Pharma’s biggest strategic move since its 2014 acquisition of Ranbaxy Laboratories, which helped cement the company’s status as India’s largest drugmaker.
Experts say the timing reflects a larger trend in the global pharmaceutical industry, where companies are racing to strengthen their product pipelines ahead of looming patent expirations for several blockbuster drugs. Reuters reported that pharmaceutical mergers and acquisitions activity has accelerated sharply in 2026 as companies seek new growth opportunities.
For Indian corporations, the acquisition reflects growing confidence in making large international bets. Analysts note that Indian firms now have stronger balance sheets, improved access to financing, and greater global ambitions than in previous decades.
Still, the acquisition comes with risks. Organon reportedly carries approximately $8.6 billion in debt, and Sun Pharma plans to finance the transaction through cash reserves and bank funding. Analysts are closely watching whether the Indian company can successfully integrate a business of Organon’s size while managing debt levels and sustaining long-term growth.
Despite those concerns, investors initially reacted positively. Reports said Sun Pharma shares rose sharply following the announcement, reflecting optimism that the acquisition could transform the company into a much larger global specialty pharmaceutical player.
The deal is expected to strengthen India’s growing reputation not just as a manufacturer of generic medicines, but as an increasingly influential force in global healthcare innovation and branded pharmaceuticals.
